Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CELZ-201

Cell therapy · Cell replacement · developed by Creative Medical Technology Holdings

Phase 1/2 Most advanced trial

CELZ Developer

1 Registered trials

What is CELZ-201?

CELZ-201 is a perinatal tissue-derived cell therapy administered via intra-arterial infusion into the pancreas. It is being studied in Type 1 Diabetes as an adjunct to standard care.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Mechanism: Cell replacement
Therapy area: Endocrine
Developer: Creative Medical Technology Holdings Inc (CELZ)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05626712	Phase 1/2	Type 1 Diabetes	Recruiting	CELZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Type 1 Diabetes

More from Creative Medical Technology Holdings

CELZ-201-DDT Phase 1/2

Sources

ClinicalTrials.gov NCT05626712

Updated Oct 3, 2026. Something wrong or missing? Report it on the CELZ page.

Follow CELZ, the company behind CELZ-201

See CELZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CELZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z